Experimental chemotherapy uses stealth tactic to activate inside cancer cells
September 24, 2026
Chemotherapy faces a fundamental problem: The same drugs powerful enough to kill cancer cells can also damage healthy tissue.
Chemotherapy faces a fundamental problem: The same drugs powerful enough to kill cancer cells can also damage healthy tissue.
Patients with relapsed or refractory multiple myeloma often run out of effective treatment options after multiple rounds of therapy.
Mount Sinai researchers have identified how APOE4, the strongest genetic risk factor for Alzheimer’s disease, damages the brain’s blood vessels and promotes the buildup of abnormal proteins linked to neurodegenerative disease.
The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.
They also found that obesity may put patients at higher risk for activation of the pathway. Drugs that block the pathway may help prevent metastasis.
The panel voted 7-2 vote in favour of GRAIL’S Galleri multi-cancer early detection (MCED) test’s benefits outweighing its risks.
Many cancer treatments work by exploiting weaknesses in tumor cells, overwhelming their ability to survive, repair damage or continue growing. Yet some cancer cells manage to survive treatment. A new study from Texas A&M University sheds light on one reason why: Some cancer cells have a survival toolkit.
Uveal melanoma is a rare, aggressive cancer that starts inside the eye and often spreads to the liver. Few treatment options exist, and unlike some forms of skin melanoma that can respond well to modern therapies, metastatic uveal melanoma (MUM) remains difficult to treat.
Pancreatic cancer does not respond to most immunotherapies, but RAS inhibitors could alter tumors to make them more sensitive to a novel immunotherapeutic approach. In pancreatic tumors with RAS mutations, RAS inhibitors cause massive cell death and reduce immunosuppression. These changes tend to be temporary because tumors develop resistance to the therapy.
A study of blood samples collected up to nine years before a cancer diagnosis found changes in the DNA that captured the body’s response to early traces of cancer development.